University of Texas MD Anderson Cancer Center:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:University of Texas MD Anderson Cancer Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11492
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:144
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of Texas MD Anderson Cancer Center (MD Anderson) is one of the leading cancer care centers in the US. It is one of the three original comprehensive cancer care centers designated by the National Cancer Act of 1971 in the US and is affiliated to University of Texas Health. MD Anderson provides cancer treatment, cancer research, education and research-based prevention of both common and rare cancers in adult and pediatric patients. Its departments include cancer biology, cancer medicine, cancer systems imaging, cancer prevention and population sciences, clinical cancer prevention, general oncology, hematopathology, gastroenterology, hepatology and nutrition, and genitourinary medical oncology, among others. MD Anderson offers undergraduate, graduate and post-graduate programs, besides research training and nursing education. It operates various research centers, labs and facilities across Texas, New Mexico and New Jersey, the US; Turkey; and Spain. MD Anderson is headquartered in Houston, Texas, the US.

University of Texas MD Anderson Cancer Center – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
University of Texas MD Anderson Cancer Center, Medical Devices Deals, 2012 to YTD 2018 13
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deal Details 22
Venture Financing 22
OncoResponse Raises Additional USD3 Million in Series A Financing 22
OncoResponse Raises USD9.5 Million in Series A Financing 24
Partnerships 26
Immatics US Enters into Licensing Agreement with MD Anderson 26
Inflection Biosciences Enters into Research Collaboration with MD Anderson Cancer Center 27
PanTher Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 28
Cyclacel Pharma Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 29
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 30
Genprex Enters into Research Agreement with University of Texas MD Anderson 31
Bayer and MD Anderson Cancer Center Enter into Agreement 32
Amgen and MD Anderson Enter Two Collaboration Agreements 33
Polaris Enters into Agreement with University of Texas MD Anderson Cancer Center 34
Humanigen Enters into Research Agreement with MD Anderson Cancer Center 35
Nanobiotix Enters into Research Agreement with University of Texas MD Anderson Cancer Center 36
The University of Texas MD Anderson Cancer Center Forms Joint Venture with Berkeley Lights 37
Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 38
Oncoceutics and University of Texas MD Anderson Cancer Center Enter into Research Agreement 39
University of Texas MD Anderson Cancer Center Forms Joint Venture with BridgeBio Pharma 40
University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 41
ConverGene Enters into Research Agreement with MD Anderson Cancer Center 42
University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 43
Kiromic Enters into Agreement with University of Texas MD Anderson Cancer Center 44
Hitachi Medical Systems America and University of Texas MD Anderson Cancer Center Enter into Research Agreement 45
Lion Biotech Enters into Agreement with MD Anderson Cancer Center 46
Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 47
Genprex Enters into Option Agreeement with University of Texas MD Anderson Cancer Center 48
University of Texas MD Anderson Cancer Center and Deerfield Management Form Joint Venture 49
EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 50
Affimed Enters into Agreement with University of Texas MD Anderson Cancer Center 51
Adaptimmune Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 52
Golden Meditech and MD Anderson to Form Joint Venture 53
Moleculin Biotech Expands its Research Agreement with University of Texas MD Anderson Cancer Center 54
BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 55
Hitachi Chemical and University of Texas MD Anderson Cancer Center Enter into Agreement 56
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 57
MorphoSys Partners with University of Texas MD Anderson Cancer Center 58
Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 59
Jiangsu Hengrui Medicine Enters into Research Agreement with University of Texas MD Anderson Cancer Center 60
Helsinn Healthcare Partners with University of Texas MD Anderson Cancer Center 61
Novocure Enters into Research Agreement with MD Anderson Cancer Center 62
Bio-Path Enters into Research Agreement with University of Texas MD Anderson Cancer Center 63
Kiromic Enters into Agreement with University of Texas MD Anderson Cancer Center 64
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 65
Mologen Enters into Agreement with The University of Texas MD Anderson Cancer Center 66
DelMar Pharma Enters into Agreement with University of Texas MD Anderson Cancer Center 67
Enumeral Biomedical Enters into R&D Agreement with University of Texas MD Anderson Cancer Center 68
X-Chem Enters into Agreement with University of Texas MD Anderson Cancer Center 69
Kymab Enters into Agreement with University of Texas MD Anderson 70
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 71
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 72
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 73
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 74
CytomX Therapeutics Enters into Agreement with University of Texas M. D. Anderson Cancer Center 75
Molecular Templates Enters into Research Agreement with MD Anderson Cancer Center 76
University of Texas MD Anderson Cancer Center and Theraclone Sciences Form Joint Venture 77
MD Anderson and Theraclone Sciences Form Joint Venture 78
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio Form Joint Venture 79
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 80
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 81
Idera Pharma Enters into Research Agreement with University of Texas 82
Concord Medical Enters into Co-Development Agreement with MD Anderson 83
Astellas Pharma Enters into Option Agreement with MD Anderson 84
Angle Enters into Agreement with MD Anderson Cancer Center 85
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 86
Amgen Enters into Research Agreement with MD Anderson 87
Genprex Enters into Option Agreeement with University of Texas MD Anderson Cancer Center, for Oncoprex therapy 88
Senior Scientific Renews Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 89
GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 90
MedImmune Enters Research Agreement With University of Texas MD Anderson 91
Genprex Enters into Agreement with University of Texas MD Anderson Cancer Center 92
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 93
Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 94
Cooper University Forms Joint Venture With University of Texas MD Anderson Cancer Center 95
Boston Strategics Enters Into Agreement With University of Texas MD Anderson Cancer Center For Oncology Drug Development 96
Cellceutix Enters Into Agreement With University of Texas MD Anderson Cancer Center For Kevetrin Drug 97
University of Texas Enters Into Co-Development Agreement With Hospital Israelita Albert Einstein 99
Licensing Agreements 100
Ipsen Enters into Licensing Agreement with MD Anderson 100
Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 101
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 102
Moleculin Biotech Enters into Licensing Agreement with MD Anderson Cancer Center 103
Cellenkos Enters Licensing Agreement with University of Texas MD Anderson Cancer Center 104
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 105
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 106
Jounce Therapeutics Amends Licensing Agreement for JTX-2011 108
GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 110
Codiak BioSciences Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 111
University of Texas MD Anderson Cancer Center – Key Competitors 112
University of Texas MD Anderson Cancer Center – Key Employees 113
University of Texas MD Anderson Cancer Center – Locations And Subsidiaries 114
Head Office 114
Other Locations & Subsidiaries 114
Joint Venture 115
Recent Developments 117
Strategy And Business Planning 117
Mar 07, 2018: MD Anderson and Berkeley Lights Launch Optera Therapeutics to Accelerate Development of Cell Therapies for Cancer 117
Jan 11, 2017: MD Anderson and Deerfield Management create Vescor to develop novel therapeutics based on inhibiting autophagy for treatment of specific cancers 118
Government and Public Interest 119
Sep 10, 2018: Study links BAP1 protein to tumor suppression in kidney, eye, bile duct and mesothelioma cancers 119
Aug 24, 2018: $50 million awarded by CPRIT to MD Anderson and its projects 120
Aug 06, 2018: Comprehensive CAR t-cell therapy pediatric guidelines developed by MD Anderson in collaboration with the pediatric acute lung injury and sepsis investigators network 121
Jun 26, 2018: Pancreatic Cancer Action Network Funds Innovative Scientists through Research Grants Program 122
May 16, 2018: Self-reporting with sensor and mobile technology may reduce symptom burden for head and neck cancer patients undergoing radiation treatment 123
May 14, 2018: New approach to cancer research aims to accelerate studies and reduce cost 124
Apr 16, 2018: Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with checkpoint blockade immunotherapies 125
Mar 02, 2018: Deeper look at biopsy exposes mutation ready to ambush drug combination 126
Jan 17, 2018: Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma 128
Nov 02, 2017: Lung Cancer Research Foundation Awards $1.6 Million in Research Grants 130
Oct 16, 2017: PROMETRIKA to Coordinate Second Phase I Trial for MD Anderson’s Institute for Applied Cancer Science 132
Aug 24, 2017: Research reveals how estrogen regulates gene expression 133
Jun 07, 2017: Innovative therapy strategy for pancreatic cancer uses engineered exosomes targeting mutated KRAS gene 134
Jun 02, 2017: Combination therapy targets genetic mutation found in many cancers 135
Feb 23, 2017: Study reveals PGK1 enzyme as therapeutic target for deadliest brain cancer 136
Feb 10, 2017: U.S. Scientists Receive Inaugural $87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 137
Product News 138
May 17, 2018: Researchers test flexible cancer research model 138
May 03, 2018: Preclinical MD Anderson study suggests ARID1a may be useful biomarker for immunotherapy 139
Feb 06, 2017: Researchers identify synthetic essentiality as novel approach for locating cancer therapy targets 141
Other Significant Developments 142
May 09, 2018: An AI Oncologist to Help Cancer Patients Worldwide 142
Appendix 144
Methodology 144
About GlobalData 144
Contact Us 144
Disclaimer 144

List of Tables
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Key Facts, 2017 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
University of Texas MD Anderson Cancer Center, Deals By Therapy Area, 2012 to YTD 2018 12
University of Texas MD Anderson Cancer Center, Medical Devices Deals, 2012 to YTD 2018 13
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
OncoResponse Raises Additional USD3 Million in Series A Financing 22
OncoResponse Raises USD9.5 Million in Series A Financing 24
Immatics US Enters into Licensing Agreement with MD Anderson 26
Inflection Biosciences Enters into Research Collaboration with MD Anderson Cancer Center 27
PanTher Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 28
Cyclacel Pharma Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 29
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 30
Genprex Enters into Research Agreement with University of Texas MD Anderson 31
Bayer and MD Anderson Cancer Center Enter into Agreement 32
Amgen and MD Anderson Enter Two Collaboration Agreements 33
Polaris Enters into Agreement with University of Texas MD Anderson Cancer Center 34
Humanigen Enters into Research Agreement with MD Anderson Cancer Center 35
Nanobiotix Enters into Research Agreement with University of Texas MD Anderson Cancer Center 36
The University of Texas MD Anderson Cancer Center Forms Joint Venture with Berkeley Lights 37
Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 38
Oncoceutics and University of Texas MD Anderson Cancer Center Enter into Research Agreement 39
University of Texas MD Anderson Cancer Center Forms Joint Venture with BridgeBio Pharma 40
University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 41
ConverGene Enters into Research Agreement with MD Anderson Cancer Center 42
University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 43
Kiromic Enters into Agreement with University of Texas MD Anderson Cancer Center 44
Hitachi Medical Systems America and University of Texas MD Anderson Cancer Center Enter into Research Agreement 45
Lion Biotech Enters into Agreement with MD Anderson Cancer Center 46
Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 47
Genprex Enters into Option Agreeement with University of Texas MD Anderson Cancer Center 48
University of Texas MD Anderson Cancer Center and Deerfield Management Form Joint Venture 49
EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 50
Affimed Enters into Agreement with University of Texas MD Anderson Cancer Center 51
Adaptimmune Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 52
Golden Meditech and MD Anderson to Form Joint Venture 53
Moleculin Biotech Expands its Research Agreement with University of Texas MD Anderson Cancer Center 54
BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 55
Hitachi Chemical and University of Texas MD Anderson Cancer Center Enter into Agreement 56
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 57
MorphoSys Partners with University of Texas MD Anderson Cancer Center 58
Ionis Pharma Partners with University of Texas MD Anderson Cancer Center 59
Jiangsu Hengrui Medicine Enters into Research Agreement with University of Texas MD Anderson Cancer Center 60
Helsinn Healthcare Partners with University of Texas MD Anderson Cancer Center 61
Novocure Enters into Research Agreement with MD Anderson Cancer Center 62
Bio-Path Enters into Research Agreement with University of Texas MD Anderson Cancer Center 63
Kiromic Enters into Agreement with University of Texas MD Anderson Cancer Center 64
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 65
Mologen Enters into Agreement with The University of Texas MD Anderson Cancer Center 66
DelMar Pharma Enters into Agreement with University of Texas MD Anderson Cancer Center 67
Enumeral Biomedical Enters into R&D Agreement with University of Texas MD Anderson Cancer Center 68
X-Chem Enters into Agreement with University of Texas MD Anderson Cancer Center 69
Kymab Enters into Agreement with University of Texas MD Anderson 70
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 71
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 72
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center 73
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 74
CytomX Therapeutics Enters into Agreement with University of Texas M. D. Anderson Cancer Center 75
Molecular Templates Enters into Research Agreement with MD Anderson Cancer Center 76
University of Texas MD Anderson Cancer Center and Theraclone Sciences Form Joint Venture 77
MD Anderson and Theraclone Sciences Form Joint Venture 78
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio Form Joint Venture 79
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 80
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 81
Idera Pharma Enters into Research Agreement with University of Texas 82
Concord Medical Enters into Co-Development Agreement with MD Anderson 83
Astellas Pharma Enters into Option Agreement with MD Anderson 84
Angle Enters into Agreement with MD Anderson Cancer Center 85
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 86
Amgen Enters into Research Agreement with MD Anderson 87
Genprex Enters into Option Agreeement with University of Texas MD Anderson Cancer Center, for Oncoprex therapy 88
Senior Scientific Renews Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 89
GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 90
MedImmune Enters Research Agreement With University of Texas MD Anderson 91
Genprex Enters into Agreement with University of Texas MD Anderson Cancer Center 92
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 93
Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 94
Cooper University Forms Joint Venture With University of Texas MD Anderson Cancer Center 95
Boston Strategics Enters Into Agreement With University of Texas MD Anderson Cancer Center For Oncology Drug Development 96
Cellceutix Enters Into Agreement With University of Texas MD Anderson Cancer Center For Kevetrin Drug 97
University of Texas Enters Into Co-Development Agreement With Hospital Israelita Albert Einstein 99
Ipsen Enters into Licensing Agreement with MD Anderson 100
Spectrum Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer 101
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 102
Moleculin Biotech Enters into Licensing Agreement with MD Anderson Cancer Center 103
Cellenkos Enters Licensing Agreement with University of Texas MD Anderson Cancer Center 104
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 105
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 106
Jounce Therapeutics Amends Licensing Agreement for JTX-2011 108
GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 110
Codiak BioSciences Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 111
University of Texas MD Anderson Cancer Center, Key Competitors 112
University of Texas MD Anderson Cancer Center, Key Employees 113
University of Texas MD Anderson Cancer Center, Other Locations 114
University of Texas MD Anderson Cancer Center, Subsidiaries 115
University of Texas MD Anderson Cancer Center, Joint Venture 115

List of Figures
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
University of Texas MD Anderson Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
University of Texas MD Anderson Cancer Center, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[University of Texas MD Anderson Cancer Center:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Curis Inc (CRIS):製薬・医療:M&Aディール及び事業提携情報
    Summary Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating human cancers with substantial unmet medical need. It has three drug candidates in development, CUDC-907 for diffuse large B-cell lymphoma (DLBCL) and solid tumors; …
  • Henry Schein Inc (HSIC):企業の財務・戦略的SWOT分析
    Henry Schein Inc (HSIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • JSR Corp (4185):製薬・医療:M&Aディール及び事業提携情報
    Summary JSR Corp (JSR), formerly Japan Synthetic Rubber Co Ltd is a chemical manufacturing company. It produces a synthetic rubbers, emulsions and plastics. The company, along with its subsidiaries, provides general-purpose synthetic rubbers, special purpose synthetic rubbers, thermoplastic elastome …
  • Futuren (FTRN):企業の財務・戦略的SWOT分析
    Futuren (FTRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Wayne State University:製薬・医療:M&Aディール及び事業提携情報
    Summary Wayne State University (WSU) is a public research university that offers academic and certificate programs for graduates and undergraduates. The university offers academic programs such as business, engineering, information science, arts and sciences, law, medicine, nursing and health scienc …
  • Eurofins MWG Operon LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Eurofins MWG Operon LLC (Eurofins) is a DNA sequencing service provider. The company offers DNA sequencing services, DNA synthesis products, and bioinformatic services. Its product categories comprise DNA and RNA synthesis, DNA sequencing, GENE synthesis and next gen seq. Eurofins provides n …
  • Industrija nafte dd (INA-R-A):石油・ガス:M&Aディール及び事業提携情報
    Summary Industrija nafte dd (INA) is an integrated energy company, which operates across the energy value chain from exploration and production to refining and marketing to retail. It has interests in offshore and onshore assets in Croatia, Egypt, and Angola. The company manages refineries in Rijeka …
  • Herbalife Nutrition Ltd (HLF):企業の財務・戦略的SWOT分析
    Herbalife Nutrition Ltd (HLF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Quantum Genomics SA (ALQGC):製薬・医療:M&Aディール及び事業提携情報
    Summary Quantum Genomics SA (Quantum Genomics) is a biopharmaceutical company which develops novel medicines in the field of cardiovascular diseases. The company develops drugs to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition (B …
  • Norsk Hydro ASA (NHY)-エネルギー分野:企業M&A・提携分析
    Summary Norsk Hydro ASA (Hydro) is a global supplier of aluminum and an electricity producer. Its operations span the value chain, from bauxite extraction to the production of rolled and extruded aluminum products and building systems. Its portfolio of products include bauxite, alumina, extrusion in …
  • IQVIA Holdings Inc (IQV):企業の財務・戦略的SWOT分析
    IQVIA Holdings Inc (IQV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Molkerei Meggle Wasserburg GmbH & Co. KG:企業の戦略・SWOT・財務情報
    Molkerei Meggle Wasserburg GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Molkerei Meggle Wasserburg GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Siemens Ltd (SIEMENS):企業の財務・戦略的SWOT分析
    Siemens Ltd (SIEMENS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析
    RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ichor Holdings Ltd (ICHR):企業の財務・戦略的SWOT分析
    Ichor Holdings Ltd (ICHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Allergy Therapeutics Plc (AGY)-製薬・医療分野:企業M&A・提携分析
    Summary Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alter …
  • Urban One Inc (UONEK):企業の財務・戦略的SWOT分析
    Urban One Inc (UONEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • MedEquities Realty Trust, Inc. (MRT):企業の財務・戦略的SWOT分析
    MedEquities Realty Trust, Inc. (MRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Mologic Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company provides products such as bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit, amon …
  • Ultrapar Participacoes S.A.:企業の戦略・SWOT・財務情報
    Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report Summary Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆